Jian Hou

Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial

Jesús F. San Miguel, Vânia Hungria, Sung‐Soo Yoon et al. · The Lancet Oncology · 2014 · 788 citations

Medicine, Pharmacology, Pharmacotherapy +15

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

Shaji Kumar, J H Lee, Juan José Lahuerta et al. · Leukemia · 2011 · 721 citations

Medicine, Hematology, Pharmacotherapy +15

Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma

Jie Xu, Lijuan Chen, Shuangshuang Yang et al. · Proceedings of the National Academy of Sciences · 2019 · 407 citations · Full text

Medicine, Hematology, Immunology +17

Role of Magnetic Resonance Imaging in the Management of Patients With Multiple Myeloma: A Consensus Statement

Meletios Α. Dimopoulos, Jens Hillengaß, Saad Z. Usmani et al. · Journal of Clinical Oncology · 2015 · 394 citations · Full text

Medicine, Hematology, Radiology +17

Exome sequencing identifies somatic mutations of DDX3X in natural killer/T-cell lymphoma

Lu Jiang, Zhaohui Gu, Zi‐Xun Yan et al. · Nature Genetics · 2015 · 378 citations

Medicine, Molecular Genetics, Oncology +14